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Abstract
Background: We previously reported a cross-sectional association between the presence of human herpesvirus 8
(HHV-8) serum antibodies and screen-detected prostate cancer in men living in Tobago. In the same study
population, we examined the association between HHV-8 seropositivity and incident prostate cancer discovered at
later screenings.
Methods: In 40-81 year-old men without prostate cancer discovered at initial digital rectal examination (DRE) and
prostate-specific antigen (PSA) screening, a case-cohort design measured the association between baseline HHV-8
seropositivity (modified immunofluorescence assay for antibodies against HHV-8 lytic antigens) and incident
prostate cancer detected at DRE and PSA screenings three or five years later.
Results: Analyses included 486 unique individuals, 96 incident prostate cancer cases, and 415 randomly selected
subjects representing an at-risk cohort. By design, the random sub-cohort contained 25 incident prostate cancer
cases. In the sub-cohort, the frequency of HHV-8 seropositivity increased across age groupings (40-49 years: 3.5%,
50-59 years: 13.6%, and ≥ 60 years: 22.9%). HHV-8 seropositivity was higher in men with elevated (≥ 4.0 ng/mL)
than men with non-elevated PSA at initial screening (30.4% vs. 9.9% seropositive; crude odds ratio (OR) 3.96, 95%
confidence interval (CI) 1.53-10.2; age-adjusted OR 2.42, 95% CI 0.91-6.47). HHV-8 seropositivity did not increase
incident prostate cancer risk (age-adjusted hazard ratio (HR) 0.88, 95% CI 0.46-1.69).
Conclusions: Case-cohort analysis did not identify association between HHV-8 seropositivity and incident prostate
cancer. However, analyses uncovered possible association between HHV-8 and PSA (a marker of prostate
inflammation). Co-occurrence of HHV-8 seropositivity and PSA elevation may explain cross-sectional association
between HHV-8 and PSA screen-detected prostate cancer.
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Background
In 2008, prostate cancer was the fifth most common
cancer and the sixth leading cause of cancer death
among men worldwide [1]. Men of African descent
experience higher prostate cancer incidence and mortal-
ity than any other racial group [1-5]. Other accepted
risk factors include older age and family history. The
otherwise poor understanding of prostate cancer
etiology motivates search for specific causal agents.
Though not consistently [6], studies find prostate cancer
in association with infectious disease agents, including
Neisseria gonorrhoeae, Chlamydia trachomatis,h u m a n
papillomavirus (HPV) type 18, and Treponema pallidum
(syphilis) [7-11]. Other studies find viral DNA or evi-
dence of viral gene expression in prostate tissues (HPV,
human herpes simplex virus type 2, cytomegalovirus,
Epstein-Barr virus, and human herpesvirus 8 (HHV-8)
[10,12-19]), stromal fibroblasts within prostate tumors
(xenotropic murine leukemia virus-related virus or
XMRV [20]), or malignant prostate epithelial cells
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immune response creating a cytokine tissue environ-
ment that leads to chronic inflammation, DNA damage,
cellular proliferation, angiogenesis, and ultimately pros-
tate cancer [10,13,22,23].
HHV-8, a DNA virus, causes Kaposi’s sarcoma and
primary effusion lymphoma. In a high prostate cancer
risk cohort of African-Caribbean men living on Tobago
[24,25], we found an association between HHV-8 sero-
positivity and prostate cancer discovered as a result of
an initial prostate cancer screening (odds ratio [OR]
2.24, 95% confidence interval [CI] 1.29-3.90) [9]. Four
studies completed later in other population settings
could not confirm an association between HHV-8 and
prostate cancer [6,11,26,27]. Therefore, our current
study re-examines this association in our Tobago study
population, through consideration of the association
between HHV-8 seropositivity and prostate cancer dis-
covered, not as a result of the initial screening, but later
as a result of subsequent screenings.
Methods
Study Population
The Tobago Prostate Survey is an ongoing population-
based longitudinal study of prostate cancer screening, as
well as risk, in ≥ 40 year-old men living in Tobago [24].
Tobago is a small Caribbean island, 7 by 26 miles in
size, with 8078 40-79 year-old men, according to a 2000
census [28]. The population as a whole is 89% African
or Black and 7% mixed heritage by nationality or ethni-
city [28]. Identification of study participants occurred
through the agency of posters, flyers, public service
announcements, public presentations, healthcare work-
ers, private physicians, and word of mouth [24]. Prostate
cancer screening occurred in three waves, Wave 1 -
October 1997 to August 2003, Wave 2 - February 1999
to August 2003, and Wave 3 - May 2004 to March
2007. Although an open cohort, this report included
only men screened at Wave 1 and subsequently
rescreened at Waves 2 and/or 3. Study procedures
included risk factor questionnaires, blood collections,
and prostate cancer screening examinations, with pros-
tate specific antigen (PSA) serum concentrations ≥ 4
ng/mL or abnormal digital rectal examinations (DRE)
prompting referral for ultrasound-guided trans-rectal
prostate biopsy [24].
Wave 1 enrolled 3264 40-81 year-old men (97% self-
reporting African descent). The current study excluded
men missing Wave 1 PSA (n = 283), men with Wave 1
PSA ≥ 4 . 0n g / m Ln o tf o l l o w e db yp r o s t a t eb i o p s y( n=
104), and men with prostate cancer detected at Wave 1
(n = 330), thereby leaving 2547 men at risk for prostate
cancer at Wave 2 or Wave 3 (Figure 1). The study
design excluded 756 at-risk men, including 633 at-risk
men without subsequent PSA at either Wave 2 or Wave
3, 108 men with a Wave 2 or Wave 3 PSA ≥ 4.0 ng/mL
not followed by biopsy, and 15 men with a prostate can-
cer negative Wave 2 biopsy, but no Wave 3 biopsy for
Wave 3 PSA ≥ 4.0 ng/mL associated with ≥ 1.0 ng/mL
PSA increase between Waves 2 and 3 (Figure 1). In the
remaining 1791 at-risk men, a Wave 2 or Wave 3 biopsy
completed before study closure (August 15, 2007)
detected prostate cancer in 109 (Figure 1).
To measure the association between Wave 1 HHV-8
seropositivity and prostate cancer detection from a
Wave 2 or Wave 3 screening, we used a case-cohort
study design that compared prostate cancer cases at
Wave 2 or Wave 3 (n = 109; Gleason 6 - 49%, Gleason
7-4 5 % ,G l e a s o n8o r9-6 % ;p r e-diagnostic screening
PSA, mean 9.5 ng/mL, median 4.4 ng/mL) against a
control group constructed as a simple random sample
(n = 442) of the 1791 at-risk men screened for prostate
cancer at Wave 2 or Wave 3. We used a case-cohort
design because research costs prohibited determination
of the HHV-8 status of all 1791 men in the at-risk
group. As a result of the random selection procedure,
27 case men with prostate cancer at Wave 2 or Wave 3
entered the sub-cohort and contributed data as controls
(Figure 1). The 442 and 1349 randomly selected and
excluded men were statistically similar with respect to
age, education, marital status, prostate cancer family his-
tory, history of smoking, personal history of cancer, his-
tory of benign prostatic hypertrophy, and Wave 1 PSA
and DRE results. The 442 men selected for the sub-
cohort survived a median 4.9 years (5
th-95
th percentile
1.7-6.8 years) between Wave 1 and the last complete
post-Wave 1 visit. For the 109 cases, a median 7.2
months (25
th-75
th percentile 2.5-13.8 months) elapsed
between pre-diagnostic screening and confirmatory
biopsy.
Study participants signed an informed consent
approved by the Institutional Review Boards of the
Tobago Division of Health and Social Services and the
University of Pittsburgh.
Laboratory Methods
Laboratory assays used frozen serum samples (thawed
once and never re-frozen) stored temporarily in a -20°C
freezer at the Tobago Health Studies office in Scarbor-
ough, Tobago, and stored later in a -80°C freezer at the
University of Pittsburgh, Department of Epidemiology.
PSA measurements used either Abbott Diagnostics
AxSYM
® or Siemens Healthcare Diagnostics ADVIA
Centaur
® immunoassays. To detect serum antibodies
against HHV-8 lytic antigens, an indirect immunofluor-
escence assay, as described elsewhere [29], used BCBL-1
cells containing the HHV-8 genome with a modified Rta
gene inducible by doxycyclin [30]. Targeting fixed and
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cate HHV-8, this assay potentially identifies any of the
lytic proteins involved in HHV-8 replication. A single
reader (FJJ), blinded to samples’ prostate cancer case
status, examined microscopic slides for fluorescence. A
positive assay result required specific fluorescence at a
1:100 dilution. Each assay run included prostate cancer
case and non-case subject sera and known HHV-8 posi-
tive and negative control sera. We tested each sample in
duplicate on separate days with disagreements resolved
by retesting on a third day. Estimates of assay sensitivity
and specificity range between 53.4-89.9% and 96.6-
97.5%, respectively [31]. Kappa agreement between first
and second assay results was 0.76 (95% CI 0.71-0.81).
Data Analysis
We used the chi-square test to evaluate 1) the statistical
significance of differences between at-risk men with
incomplete vs. complete follow-up with respect to base-
line factors such as age, education, marital status, family
history of prostate cancer, history of smoking, cancer,
and benign prostatic hypertrophy, and results from PSA
and DRE screening and 2) the statistical significance of
differences in the sub-cohort rates of HHV-8 seroposi-
tivity with respect to the same baseline factors. In ana-
lyses restricted to sub-cohort members, logistic
regression estimated odds ratios to express strengths of
association between Wave 1 PSA elevation and Wave 1
HHV-8 seropositivity, two factors determined at the
same point in time. We used Cox proportional hazards
models (Breslow weighted denominator method) for
case-cohort designs to estimate hazard ratio [HR] mea-
sures of unadjusted and age-adjusted association
between HHV-8 seropositivity measured at baseline
(Wave 1) and prostate cancer detected later in time, at
Wave 2 or Wave 3 [32]. These models compare prostate
cancer cases detected at one or the other points in time
(Wave 2 or Wave 3) with the appropriate risk set, con-
structed from sub-cohort members disease-free and
available at Wave 2 or Wave 3. For prostate cancer
cases in the sub-cohort, Cox models started follow-up at
the Wave 1 screening date and censored follow-up at
t h eW a v e2o rW a v e3s c r e e n i ng date that led to pros-
tate cancer diagnosis. For non-cases in the sub-cohort,
Cox models started follow-up at the Wave 1 screening
date and censored follow-up at the date of the last
Screened for incident 
prostate cancer 
n=1791
Anti-HHV-8 assay 
completed, n=96
Anti-HHV-8 assay completed, n=415 (includes 
n=25 with incident prostate cancer)
Incident prostate 
cancer, n=109
Random sub-cohort, n=442 (includes 
n=27 with incident prostate cancer)
40-81 year-old Tobago 
Prostate Survey 
enrollees, n=3264
No Wave 1 PSA, n=283
No biopsy for a Wave 1 PSA4 ng/mL, n=104
Prostate cancer at Wave 1, n=330
At risk for incident 
prostate cancer 
n=2547
No post-Wave 1 PSA, n=633
Any post-Wave 1 PSA4 ng/mL and no biopsy, n=108
No prostate cancer on Wave 2 biopsy, Wave 3 PSA4
     ng/mL, Wave 2 to Wave 3 PSA change 1 ng/mL,
     and no Wave 3 biopsy, n=15
Figure 1 Case-cohort design. Study design features, identifying study exclusions, the study population screened for incident prostate cancer,
the case group, and the random sub-cohort.
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Page 3 of 9completed Wave 2 or Wave 3 screening. Calculating age
on the date of the Wave 1 PSA blood collection, age
adjustments used either two age categories (40-59 and ≥
60 years), three age categories (40-49, 50-59, or ≥ 60
years), four age categories (40-44, 45-49, 50-59, and ≥
60 years), or age (integer years) modeled as a continu-
ous variable. Statistical inferences used a p = 0.05 two-
sided significance level.
Results
Table 1 summarizes the characteristics of all 3264 40-81
year-old men enrolled at Wave 1. The current study
excluded 717 men missing a Wave 1 PSA, men with
Wave 1 PSA ≥ 4.0 ng/mL not followed by prostate
biopsy, and men with prostate cancer detected at Wave
1, leaving 2547 screen-negative men at risk for prostate
cancer at Wave 2 or Wave 3 (Figure 1). Table 1 compares
these 2547 at-risk men with the 717 men who were either
inadequately screened at Wave 1 or discovered to have
prostate cancer at Wave 1. At-risk men were younger
and better educated (Table 1). At-risk men less often
reported a history of smoking, cancer, or benign prostatic
hypertrophy (Table 1). PSA values were lower and DRE
results positive less often in at-risk men, as expected,
since the group not at risk included men with prostate
cancer detected as direct result of PSA elevation or DRE
a b n o r m a l i t y( T a b l e1 ) .T h es t u d yd e s i g ne x c l u d e d7 5 6
men from the group of 2547 at-risk men eligible for fol-
low-up (Figure 1). As shown in Table 1 the 756 at-risk
men with incomplete follow-up differed from the 1791
men with complete follow-up, as follows, age (35.6% vs.
26.0% ≥ 60 years), smoking history (48.5% vs. 39.6%), per-
sonal cancer history (1.3% vs.0 . 3 % ) ,W a v e1P S A≥ 4n g /
mL (13.5% vs.5 . 5 % ) ,a n dW a v e1D R E( 6 4 . 7 %vs. 76.3%
negative and 20.0% vs. 10.3% missing).
Wave 1 HHV-8 serologic status was available for 415
(93.9% of 442) men in the sub-cohort and for 96 (88.1%
of 109) men in the case group (Gleason 6 - 49%, Gleason
7 - 45%, Gleason 8 or 9 - 6%; pre-diagnostic PSA, mean
10.0 ng/mL and median 4.4 ng/mL). Table 2 summarizes
the baseline characteristics for these men with non-miss-
ing HHV-8. In addition, Table 2 compares sub-cohort
rates of HHV-8 seropositivity according to the same
baseline characteristics. Referenced against the sub-
cohort, characteristics of the case group included older
age, less frequent smoking history, more frequent benign
prostatic hypertrophy history, more frequently elevated
Wave 1 PSA (27.1% vs.5 . 5 %P S A≥ 4n g / m L ) ,a n dm o r e
frequently positive Wave 1 prostate cancer screening
(43.8% vs. 16.9% DRE or PSA positive). Case and sub-
cohort HHV-8 seropositivity rates were 17.7% and 11.1%,
respectively. When compared with 40-49 year-old sub-
cohort men (3.5% HHV-8 seropositive), HHV-8 seroposi-
tivity was higher in 50-59 year-old sub-cohort men
(13.6% HHV-8 seropositive) and higher yet in ≥ 60 year-
old sub-cohort men (22.9% HHV-8 seropositive). HHV-8
seropositivity rates were lower in sub-cohort men with a
history of smoking than those without (7.1% vs. 13.9%)
and higher in sub-cohort men with a history of benign
prostatic hypertrophy than those without (24.0% vs.
10.5%). HHV-8 seropositivity increased with Wave 1 PSA
(7.6%, 12.1%, 12.7%, and 30.4% for PSA 0.0-0.9, 1.0-1.9,
2.0-3.9, and ≥ 4 ng/mL, respectively). HHV-8 seropositiv-
ity was higher in men with elevated (≥ 4.0 ng/mL) than
men with non-elevated PSA (30.4% vs. 9.9% seropositive;
crude OR 3.96, 95% CI 1.53-10.2; age-adjusted OR 2.42,
95% CI 0.91-6.47; data not shown). HHV-8 seropositivity
was higher in sub-cohort men with a positive than in
men with a negative Wave 1 prostate cancer screen result
(20.0% vs. 9.3% seropositive).
Table 3 compares Wave 1 HHV-8 seropositivity
between the case and sub-cohort groups, according to
age and Wave 1 PSA. Age-specific HHV-8 seropositivity
rates were lower in case than sub-cohort men (40-49
years: 0.0% vs. 3.5% and 50-59 years: 10.8% vs. 13.6%),
except in the oldest age group (≥ 60 years: 27.7% vs.
22.9%). In men with a non-elevated (< 4 ng/mL) Wave
1 PSA, the HHV-8 seropositivity rate was higher in the
case group (17.1% vs. 9.9%). In men with an elevated (≥
4 ng/mL) Wave 1 PSA, however, the HHV-8 seroposi-
tivity rate was lower in the case group (19.2% vs. 30.4%).
In the two age sub-groups with appreciable HHV-8 ser-
opositivity, age-specific HHV-8 seropositivity rates were
not consistently higher or lower in case than sub-cohort
men with non-elevated Wave 1 PSA (50-59 years: 11.5%
vs. 13.7% and ≥ 60 years: 28.1% vs. 20.4%) and consis-
tently lower in case than sub-cohort men with elevated
Wave 1 PSA (50-59 years: 9.1% vs. 12.5% and ≥ 60
years: 26.7% vs. 41.7%).
Table 4 shows associations, unadjusted and age-
adjusted, between Wave 1 HHV-8 seropositivity and
prostate cancer at Wave 2 or Wave 3, overall and in
sub-groups defined by Wave 1 screen results. Though
not statistically significant, HR point estimates indicate
lower prostate cancer risk in HHV-8 seropositive men,
overall (age-adjusted HR 0.88, 95% CI 0.46-1.69) and in
HHV-8 seropositive men with elevated Wave 1 PSA
(age-adjusted HR 0.39, 95% CI 0.10-1.63), and equiva-
lent risk in HHV-8 seropositive men with non-elevated
Wave 1 PSA (age-adjusted HR 1.03, 95% CI 0.49-2.16).
In men eligible for prostate biopsy at Wave 1 (DRE or
PSA positive), HHV-8 seropositivity reduced risk (age-
adjusted HR 0.59, 95% CI 0.18-1.91) to a statistically
insignificant level. In perhaps the most meaningful sub-
group, men not eligible for prostate biopsy at Wave 1
(DRE not positive and PSA < 4.0 ng/mL), analyses sup-
plied no evidence of association between seropositivity
and prostate cancer risk (age-adjusted HR: 1.02, 95% CI
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gle-year-of-age-adjusted (continuous) risk estimates
were HR 0.80 (95% CI 0.19-3.34) and HR 1.27 (95% CI
0.50-3.25) for the 50-59 and ≥ 60 year-old men,
respectively (data not shown). Using all (96 case and
415 sub-cohort) men or only ≥ 45 year-old (95 case and
312 sub-cohort) men made no meaningful difference in
the age-adjusted risk estimates (data not shown).
Table 1 Characteristics of all men enrolled at Wave 1, men not at risk and at risk for prostate cancer at Wave 2 or
Wave 3 based on Wave 1 screen results, and at-risk men with incomplete and complete follow-up.
Risk status after Wave 1 Follow-up
All Not at risk At risk Incomplete Complete
n = 3264 n = 717 n = 2547 n = 756 n = 1791
Characteristic n
1 %n
1 %n
1 %n
1 %n
1 % p-value
2
Demographic
Age (years) <.0001
40-44 624 19.1 59 8.2 565 22.2 151 20.0 414 23.1
45-49 571 17.5 71 9.9 500 19.6 115 15.2 385 21.5
50-59 914 28.0 166 23.2 748 29.4 221 29.2 527 29.4
60-81 1155 35.4 421 58.7 734 28.8 269 35.6 465 26.0
Education (23) (7) (16) (7) (9) 0.76
≤11 years 2411 74.4 553 77.9 1858 73.4 553 73.8 1305 73.2
12+ years 830 25.6 157 22.1 673 26.6 196 26.2 477 26.8
Marital status (26) (10) (16) (7) (9) 0.13
ever married 2669 82.4 590 83.5 2079 82.1 602 80.4 1477 82.9
never married 569 17.6 117 16.5 452 17.9 147 19.6 305 17.1
Family history of ...
Prostate cancer 0.02
missing 323 9.9 77 10.7 246 9.7 86 11.4 160 8.9
yes 218 6.7 40 5.6 178 7.0 64 8.5 114 6.4
no 2723 83.4 600 83.7 2123 83.4 606 80.2 1517 84.7
History of ...
Smoking (21) (7) (14) (3) (11) <.0001
yes 1410 43.5 341 48.0 1069 42.2 365 48.5 704 39.6
no 1833 56.5 369 52.0 1464 57.8 388 51.5 1076 60.4
Cancer (43) (13) (30) (9) (21) 0.002
yes 26 0.8 11 1.6 15 0.6 10 1.3 5 0.3
no 3195 99.2 693 98.4 2502 99.4 737 98.7 1765 99.7
Benign prostatic hypertrophy (84) (24) (60) (17) (43) 0.67
yes 248 7.8 78 11.3 170 6.8 53 7.2 117 6.7
no 2932 92.2 615 88.7 2317 93.2 686 92.8 1631 93.3
Entry prostate cancer screen
PSA (ng/mL) (190) (190) <.0001
0.0-0.9 1213 39.5 43 8.2 1170 45.9 306 40.5 864 48.2
1.0-1.9 850 27.7 45 8.5 805 31.6 206 27.2 599 33.4
2.0-2.9 268 8.7 21 4.0 247 9.7 84 11.1 163 9.1
3.0-3.9 150 4.9 26 4.9 124 4.9 58 7.7 66 3.7
4.0-9.9 354 11.5 199 37.8 155 6.1 73 9.7 82 4.6
10+ 239 7.8 193 36.6 46 1.8 29 3.8 17 0.9
DRE <.0001
missing 555 17.0 220 30.7 335 13.2 151 20.0 184 10.3
positive 636 19.5 279 38.9 357 14.0 116 15.3 241 13.5
negative 2073 63.5 218 30.4 1855 72.8 489 64.7 1366 76.3
PSA - prostate-specific antigen, DRE - digital rectal examination
1. Numbers in parentheses indicate missing data
2. Statistical significance (chi-square) of differences between at-risk men with incomplete and complete follow-up
McDonald et al. Infectious Agents and Cancer 2011, 6:25
http://www.infectagentscancer.com/content/6/1/25
Page 5 of 9Discussion
Our previous study used an immunofluorescence assay
to measure HHV-8 antibodies in 138 prostate cancer
cases and in 140 age-matched controls [9]. HHV-8 sero-
positivity was significantly more frequent in cases than
controls (39.9% vs. 22.9%, OR 2.24, 95% CI 1.29-3.90)
[9]. Our previous study compared Wave 1 screen-
detected (DRE positive and/or PSA elevated) prostate
cancer cases with DRE negative and PSA non-elevated
controls. In the same Tobago study population, using a
Table 2 Case and sub-cohort group characteristics, with sub-cohort rate of HHV-8 seropositivity, according to baseline
characteristic
Cases (n = 96) Sub-cohort (n = 415) Sub-cohort HHV-8 Pos
Characteristic n
1 Col % n
1 Col % n
1 Row % p-value
2
Demographic < .0001
Age (years)
40-49 12 12.5 200 48.2 7 3.5
50-59 37 38.5 110 26.5 15 13.6
60-81 47 49.0 105 25.3 24 22.9
Education (2) (0) 0.83
≤11 years 77 80.2 318 77.0 36 11.3
12+ years 19 19.8 95 23.0 10 10.5
Marital status 0.48
ever married 82 85.4 336 81.0 39 11.6
never married 14 14.6 79 19.0 7 8.9
Family history of ...
Prostate cancer 0.80
missing 5 5.2 32 7.7 4 12.5
yes 5 5.2 27 6.5 2 7.4
no 86 89.6 356 85.8 40 11.2
History of ...
Smoking (1) (0) 0.029
yes 34 35.4 170 41.1 12 7.1
no 62 64.6 244 58.9 34 13.9
Benign prostatic hypertrophy (3) (8) (0) 0.039
yes 10 10.8 25 6.1 6 24.0
no 83 89.2 382 93.9 40 10.5
Entry prostate cancer screen
PSA (ng/mL) 0.010
0.0-0.9 7 7.3 197 47.5 15 7.6
1.0-1.9 27 28.1 140 33.7 17 12.1
2.0-3.9 36 37.5 55 13.3 7 12.7
≥ 4.0 26 27.1 23 5.5 7 30.4
DRE 0.34
missing 4 4.2 48 11.6 4 8.3
positive 29 30.2 54 13.0 9 16.7
negative 63 65.6 313 75.4 33 10.5
DRE positive and/or PSA ≥ 4 ng/mL 0.009
yes 42 43.8 70 16.9 14 20.0
no 54 56.3 345 83.1 32 9.3
Study-specific
HHV-8 sero-status
positive 17 17.7 46 11.1
negative 79 82.3 369 88.9
PSA - prostate-specific antigen, DRE - digital rectal examination, HHV-8 - human herpesvirus 8
1. Numbers in parentheses indicate missing data
2. Statistical significance (chi-square) of differences in HHV-8 seropositivity according to baseline characteristic
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offered an opportunity to evaluate temporal relation-
ships between HHV-8 seropositivity and prostate cancer,
in men with and without elevated PSA at baseline.
Including men with non-elevated (< 4.0 ng/mL) Wave 1
PSA and men with elevated (≥ 4.0 ng/mL) Wave 1 PSA,
but prostate cancer not seen on Wave 1 biopsy, case-
cohort analysis did not observe HHV-8-related incident
prostate cancer risk in men overall (age-adjusted HR
0.88, 95% CI 0.46-1.69), in men with Wave 1 PSA < 4
ng/mL (age-adjusted HR 1.03, 95% CI 0.49-2.16), or in
men without a positive Wave 1 prostate cancer screen
result (age-adjusted HR 1.02, 95% CI 0.44-2.39; Table 4).
A positive association between HHV-8 seropositivity
and prevalent prostate cancer in a cross-sectional study
[9] and an inverse (though not statistically significant)
association in a prospective study, an inverse association
most evident in men sent for biopsy (e.g., PSA ≥ 4n g /
mL, age-adjusted HR 0.39, 95% CI 0.10-1.63; Table 4),
lead to the following speculation. HHV-8 may associate
with factors, such as elevated PSA, that prompt biopsy
and subsequent recognition of prostate cancer. In effect,
HHV-8 may segregate men with manifest and emergent
prostate cancer into two groups, HHV-8 seropositive
prostate cancer detected immediately and HHV-8 sero-
negative prostate cancer detected later. This selection
bias may explain opposing positive and negative HHV-8
associations seen with prevalent and incident prostate
cancer, respectively. A similar selection bias may explain
inverse associations between HHV-8 and prostate cancer
observed in other prospective studies, as described
below.
Four comparative studies of HHV-8 and prostate can-
cer have appeared [6,11,26,27] since our 2004 publica-
tion [9]. In a prospective study from Finland, ELISA
detected serum antibodies against the HHV-8 ORF65
protein in 3 (1.8%) of 163 men with incident prostate
cancer and in 7 (2.4%) of 288 age-matched men without
cancer (OR 0.74, 95% CI 0.19-2.88; [27]). In a U.S.
population-based case-control study, the immunofluor-
escence assay detected serum antibodies against HHV-8
lytic antigens less often in cases than controls (95 Afri-
can-American cases and 75 controls: OR 0.56, 95% CI
0.28-1.14; 104 white cases and 80 controls: OR 0.71,
95% CI 0.36-1.43; [26]). In a study of 691 individually
matched case-control pairs nested within the U.S.
Health Professional Follow-up Study, the immunofluor-
escence assay detected plasma antibodies against lytic
antigens less often in men diagnosed with prostate can-
cer, on average, 3.1 years later (OR 0.70, 95% CI 0.52-
0 . 9 5 ;[ 6 ] ) .F i n a l l y ,i nt h eP r o s t a t e ,L u n g ,C o l o r e c t a l ,a n d
Ovarian (PLCO) Cancer Screening Trial, ELISA detected
IgG antibodies against the HHV-8 K8.1 structural pro-
tein in study entry serum samples from 103 (13.5%) of
765 and 103 (11.3%) of 915 white prostate cancer cases
Table 3 Sub-cohort and case group Wave 1 HHV-8
seropositivity, by age and Wave 1 PSA result
Cases Sub-cohort
Age years PSA ng/mL HHV-8 positive HHV-8 positive
nn % nn %
40-49 All 12 0 0.0 200 7 3.5
50-59 All 37 4 10.8 110 15 13.6
≥ 60 All 47 13 27.7 105 24 22.9
All < 4 70 12 17.1 392 39 9.9
All ≥ 4 26 5 19.2 23 7 30.4
40-49 < 4 12 0 0.0 197 6 3.0
50-59 < 4 26 3 11.5 102 14 13.7
≥ 60 < 4 32 9 28.1 93 19 20.4
40-49 ≥ 4 3 1 33.3
50-59 ≥ 4 11 1 9.1 8 1 12.5
≥ 60 ≥ 4 15 4 26.7 12 5 41.7
PSA - prostate-specific antigen, DRE - digital rectal examination, HHV-8 -
human herpesvirus 8
Table 4 Unadjusted and age-adjusted associations (hazard ratio) between Wave 1 HHV-8 seropositivity and prostate
cancer at Wave 2 or Wave 3, overall and within strata defined by Wave 1 prostate cancer screening test results
Wave 1 prostate cancer screening test result Cases Sub-cohort Unadjusted Age-adjusted
Pos n Pos n HR 95% CI HR 95% CI
Overall 17 96 46 415 1.46 0.78-2.74 0.88
1 0.46-1.69
PSA (ng/mL)
< 4 12 70 39 392 1.61 0.77-3.38 1.03
1 0.49-2.16
≥ 4 5 26 7 23 0.44 0.11-1.71 0.39
2 0.10-1.63
DRE positive or PSA ≥ 4 ng/mL
no 9 54 32 345 1.67 0.72-3.86 1.02
1 0.44-2.39
yes 8 42 14 70 0.85 0.52-2.38 0.59
3 0.18-1.91
Pos - number HHV-8 positive, n - case or sub-cohort count, HR - hazard ratio, CI - confidence interval, PSA - prostate-specific antigen, DRE - digital rectal
examination
1. Adjusted across four age categories: 40-44, 45-49, 50-59, ≥ 60 years
2. Adjusted across two age categories: 40-59, ≥ 60 years
3. Adjusted across three age categories: 40-49, 50-59, ≥ 60 years
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Page 7 of 9and age-matched controls, respectively (OR 1.3, 95% CI
0.9-1.7) and in 2 (1.9%) of 103 and 22 (6.0%) of 367
black cases and age-matched controls, respectively (OR
0.3, 95% CI 0.1-1.4; [11]). On balance, these studies sug-
gest that HHV-8 does not influence prostate cancer risk.
Analyses restricted to the sub-cohort showed strong
association 1) between HHV-8 seropositivity and
increasing age, a result also seen in Tobago women [33]
and many other populations [34,35], and 2) between
HHV-8 seropositivity and PSA elevation ≥ 4.0 ng/mL.
Though not statistically significant (p = 0.17), age-
adjusted geometric mean Wave 1 PSA was 18% higher
in HHV-8 seropositive than seronegative sub-cohort
men (data not shown). The age-adjusted odds of HHV-8
seropositivity was more than two-fold higher in sub-
cohort men with elevated PSA than men with non-ele-
vated PSA. Personal or environmental factors related to
HHV-8 exposure or immune function may explain the
age association with HHV-8 [33]. Accepting PSA as a
marker of prostate inflammation, we postulate that the
association between HHV-8 seropositivity and elevated
PSA signifies either the effects of HHV-8 infection on
prostate inflammation [19] or the effects of prostate
inflammation on HHV-8 reactivation. PSA elevation has
been observed in relation to other infectious disease
agents [36,37].
Study strengths include unique population and setting
(predominantly African ancestry Tobago residents [38])
and a control group large enough to estimate age-speci-
fic HHV-8 seroprevalence rates with acceptable preci-
sion. Study limitations include unavoidable
misclassification according to prostate cancer outcome.
DRE and PSA invariably miss instances of biopsy detect-
able prostate cancer. The Prostate Cancer Prevention
Trial, for example, observed a 15% prostate cancer
biopsy prevalence in men with PSA ≤4 ng/mL [39]. In
addition, our study can not define the prostate cancer
risk experience of men who did not return for repeat
screening. Follow-up intervals much longer than our
five-year interval between initial and final screening may
be needed to detect a prostate cancer effect from any
chronic inflammation caused by HHV-8 infection. Also,
HHV-8 may cause inflammation and prostate cancer
only in a relatively small genetically susceptible sub-
group. Finally, a small case count limits, especially in
sub-groups, the precision of our risk estimates. For
example, in men not eligible for prostate biopsy at
Wave 1, the 95% confidence interval embraced both
50% lower and 200% higher prostate cancer risks in
relation to HHV-8 seropositivity.
Conclusions
Our prospective study could not demonstrate an asso-
ciation between HHV-8 seropositivity and incident
prostate cancer. However, analyses uncovered a strong
relationship between elevated HHV-8 seropositivity and
PSA. The HHV-8 association previously observed with
prevalent prostate cancer may signify enhanced detec-
tion of prostate cancer possibly caused by the effects of
HHV-8 on PSA. In this context, the association we
observed between HHV-8 seropositivity and PSA eleva-
tion deserves further study.
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